Brought to you by INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA





Back

Unraveling Potential Compounds of Uncaria gambir (W.Hunter) Roxb. as Antikeloid Agent: In Silico, In Vitro and Ex Vivo Experimental Validation

Abstract

Document

Background/Objectives: Keloid treatment remains challenging due to limited effectiveness and patient dissatisfaction. Herbal-based therapy offers promising alternatives that require further investigation. Uncaria gambir (W.Hunter) Roxb., an original plant from Indonesia, possesses an antifibrotic effect. However, its potential as an antifibrotic agent in keloid management remains unclear. This study aims to bridge this gap by evaluating the bioactive compound from gambir and its effects on keloid fibroblast primary culture. Methods: The bioactive compounds of gambir extract and fractions (ethanol, hexane, and ethyl acetate fractions) were identified by using liquid chromatography—mass spectrometry (LCMS/MS) analysis. The mechanism of gambir bioactive

References (35)

Similar documents

Impact

Cited by (0)

compounds for keloid was predicted using the compound–protein interaction network and enrichment analysis, and validated using molecular docking and dynamic simulation. The experimental study results, including cytotoxic and bioactivity effects, were represented as IC_{50} and selectivity index (SI) values, and the ex vivo analysis of keloid tissue explants. Results: Uncariagambiriine was identified as the most potent compound with the lowest binding energy and high stability to the core protein targets: AKT1 and TGFB1. The ethanol fraction was determined to have the highest abundance of gambir's typical bioactive compounds, with the lowest IC_{50} (128.76 \pm 0.24 μ g/mL) and the highest SI (6.32) value. Furthermore, the results of the ex vivo analysis indicated the significant inhibition of keloid fibroblast proliferation and migration by the gambir ethanolic fraction. Conclusions: This study underlines the potential of the gambir ethanolic fraction as an antifibrotic agent in keloid, warranting further investigation and development for clinical applications. © 2025 by the authors.

Author keywords

bioactive compounds; bioactivity; gambir; keloid

Funding details

Details about financial support for research, including funding sources and grant numbers as provided in academic publications.

Funding sponsor	Funding number	Acronym
Universitas Indonesia See opportunities by UI 🗷	NKB-260/UN2.RST/HKP.05.00/2024	UI
Universitas Indonesia See opportunities by UI 🗷		UI

Funding text

This study was supported by Universitas Indonesia (PUTI 2024 grant; grant number: NKB-260/UN2.RST/HKP.05.00/2024).

Corresponding authors

Corresponding
author

Affiliation
Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas
Indonesia, Jakarta, 10430, Indonesia
Email address
fadilah.msi@ui.ac.id

© Copyright 2025 Elsevier B.V., All rights reserved.

Abstract

Author keywords

Funding details

Corresponding authors

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us